Coeliac Disease Trial, Recruiting (NCT07585669)

Coeliac Disease Trial, Recruiting NCT07585669 Sponsor: University of Chile Condition: Coeliac Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07585669 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Coeliac Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 65 years old
You have recently been diagnosed with celiac disease, confirmed through blood tests and a small bowel tissue sample (biopsy)
You have not yet started following a gluten-free diet
You are willing to follow a supervised gluten-free diet throughout the study
You are able to give your written agreement (consent) to take part

Who may not be able to join:

You are already following, or have previously followed, a gluten-free diet
You have taken omega-3 fish oil supplements or other supplements that affect inflammation in the last 3 months
You have another autoimmune, inflammatory, or gut condition, such as Crohn's disease or ulcerative colitis
You are currently pregnant or breastfeeding
You have a serious ongoing illness that could affect the study, such as uncontrolled diabetes or cancer
You have an allergy or intolerance to fish oil or any ingredient in the study supplement
You have used medications that suppress the immune system or reduce inflammation in the last 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +56 2 9773232

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07585669

Sponsor: University of Chile

Phase: Not Applicable

Status: Recruiting

Condition: Coeliac Disease

Trial contact: +56 2 9773232

More information: https://clinicaltrials.gov/study/NCT07585669

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 65 years old
You have recently been diagnosed with celiac disease, confirmed through blood tests and a small bowel tissue sample (biopsy)
You have not yet started following a gluten-free diet
You are willing to follow a supervised gluten-free diet throughout the study
You are able to give your written agreement (consent) to take part

Who may not be able to join:

You are already following, or have previously followed, a gluten-free diet
You have taken omega-3 fish oil supplements or other supplements that affect inflammation in the last 3 months
You have another autoimmune, inflammatory, or gut condition, such as Crohn's disease or ulcerative colitis
You are currently pregnant or breastfeeding
You have a serious ongoing illness that could affect the study, such as uncontrolled diabetes or cancer
You have an allergy or intolerance to fish oil or any ingredient in the study supplement
You have used medications that suppress the immune system or reduce inflammation in the last 3 months

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Chile

Registry

ClinicalTrials.gov

Start date

1 October 2025

Est. completion

30 October 2026

Where this trial is recruiting

🇨🇱 Chile

Primary endpoints

Modulation of systemic inflammatory response via cytokine levels and NF-κB signaling in peripheral blood mononuclear cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov